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Abstract
In the clinic, the diagnosis of Parkinson’s disease (PD) largely depends on clinicians’ experience. When the diagnosis
is made, approximately 80% of dopaminergic cells in the substantia nigra (SN) have been lost. Additionally, it is rather
challenging to differentiate PD from atypical parkinsonian disorders (APD). Clinially-available 3T conventional MRI
contributes little to solve these problems. The pathologic alterations of parkinsonism show abnormal brain iron
deposition, and therefore susceptibility-weighted imaging (SWI), which is sensitive to iron concentration, has
been applied to find iron-related lesions for the diagnosis and differentiation of PD in recent decades. Until
now, the majority of research has revealed that in SWI the signal intensity changes in deep brain nuclei,
such as the SN, the putamen (PUT), the globus pallidus (GP), the thalamus (TH), the red nucleus (RN) and
the caudate nucleus (CN), thereby raising the possibility of early diagnosis and differentiation. Furthermore,
the signal changes in SN, PUT and TH sub-regions may settle the issues with higher accuracy. In this article,
we review the brain iron deposition of PD, MSA-P and PSP in SWI in the hope of exhibiting a profile of SWI
features in PD, MSA and PSP and its clinical values.
Keywords: Parkinson’s disease, Multiple system atrophy Parkinsonian predominant type, Progressive
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Background
Parkinson’s disease (PD) is characterized by resting
tremor, rigidity, bradykinesia and postural instability
accompanied by non-motor symptoms [1]. The criteria
for PD diagnosis largely relay on clinicians’ experience,
and an accurate diagnosis often needs 3 to 5 years of
follow-up. When PD is diagnosed, approximately 80% of
dopaminergic cells in the substantia nigra pars compacta
(SNc) have been lost [2]. Researches miss the opportunity
for unraveling the mechanism of PD in the early stage
to develop disease-modifying therapy which is deemed
to prevent the disease progression or complications,
though no such therapy exists at present [3]. On the
other hand, atypical parkinsonian disorders (APD) are
a group of heterogeneous neurodegenerative diseases
including multiple system atrophy parkinsonian predom-
inant type (MSA-P), progressive supranuclear palsy (PSP),
and others. However, in the early stage of parkinsonism,
PD and APD often show similar symptoms that are
extremely difficult to distinguish, even for experienced
neurologists [4]. Thus, it is critical to find the biomarkers
for the diagnosis and differentiation of PD in the early
stage. In the clinic, the biomarkers detected by positron
emission tomography (PET) and single photon emission
computed tomography (SPECT) can directly visualize
the loss of dopaminergic cells [5, 6]. However, MRI is
less expensive, non-invasive and avoids the radiation of
radiotracers compared with PET and SPECT. During the
past decades, a number of imaging signs were found by
conventional MRI such as the “swallow tail sign”, the
pontine atrophy, the “hummingbird sign”, etc. Although
the specificities of these signs are high, the sensitivities
are highly magnetic-intensity dependent [7–9]. The
ultra-high field MRI is not wildly accepted in clinic as
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the results of the high expense and potential security
problems.
The most ideal biomarkers must be involved in the
pathologic changes of PD and APD such that the poten-
tial biomarkers can indicate the underlying pathologic
processes. The abnormal iron deposition in the deep
brain nuclei in parkinsonism was first described by
Lhermitte et al. in 1924 [10]. Most studies have discovered
that iron increases consistently in SN of PD, and the
iron content is associated with disease severity [11].
Recently, abnormal iron deposition was also found in
APD such as MSA-P, PSP and others [12–15]. Interes-
tingly, the regions that are rich in iron among neuro-
degenerative diseases vary from each other [15, 16]. Iron
may play a key role in the neuropathology of neurodege-
nerative diseases [12]. Therefore, the iron concentration
and iron distribution in deep brain nuclei may work as
promising biomarkers in PD and APD. Also, iron can
change the magnetic susceptibility of tissues where it
deposits. Susceptibility-weighted imaging (SWI), a novel
MRI technique, is sensitive to magnetic susceptibility of
tissue, and thus can detect the iron-related information of
neurodegenerative parkinsonism working as a promising
detecting tool in PD and APD [16, 17]. Here we review
about brain iron deposition of PD, MSA-P and PSP
in SWI in the hope of exhibiting a profile of SWI feature
in PD, MSA and PSP and its clinical values.
Susceptibility-weighted imaging
SWI exploits the differences in magnetic susceptibility of
tissues, which describes the magnetic response of tissues
placed in an external magnetic field, to develop an
enhanced image contrast for conventional MRI [18–20].
By applying a gradient-recalled echo (GRE) sequence with
relatively long echo time (TE), a SW image combines a
phase image with a magnitude image under high-intensity
magnetic field such as 3T and 7T, to add the magnetic
susceptibility information to the structure of the brain
in situ (as shown in Fig. 1) [19]. The high-intensity field
ensures a high spatial resolution and contrast-to-noise
ratio for the further study of detailed structures in the
brain [21]. Image phase variations reflect the static
magnetic field inhomogeneities, which are influenced
by a macroscopic effect and a microscopic effect [19, 22].
The macroscopic effect, also called the geometry effect, is
that the configuration of tissues, such as white matter
tract, capillary beds, the interstitial space and others,
distorts the homogeneity of the local field [19, 22, 23].
The microscopic effect is described as the homogeneity of
the local field being distorted by substances with different
magnetic susceptibility [18, 19, 22, 24]. Thus, the variances
in the magnetic susceptibility of tissues are derived
from both the geometry of the tissue and the substances’
reaction to the applied field.
According to the reaction to the applied field, the
substances can be classified into paramagnetic and dia-
magnetic. The paramagnetic substances mainly include
ferritin containing ferric iron, deoxygenated hemoglobin,
and ceruloplasmin, while the diamagnetic ones include
myelin, calcium, and oxygenated hemoglobin [23]. Gene-
rally, the grey matter is paramagnetic because of the iron,
and the white matter is diamagnetic due to the myelin
[25, 26]. In comparison, iron has the highest concentra-
tion in the deep grey nuclei, while the other substances
are relatively minimal [12]. Abnormal iron deposition
patterns were found in the brain of patients with parkin-
sonism. Excess iron can cause damage to neuron through
free radical production [13, 27, 28]. Therefore, iron is
thought to play a key role in the pathogenesis of neuro-
degenerative parkinsonism [12, 13, 28, 29]. The abnormal
iron deposition results in changed iron distribution and
concentration in the brain, and thereby changing the
susceptibility of tissue. SWI is able to identify the suscep-
tibility alteration through recording the phase changes
caused by the iron deposition through the multiplication
of phase image with magnitude image for several times,
which enables the increasing of phase contrast and indi-
rect evaluation of iron content in parkinsonism [30–33].
What’s more, the sensitivity of SWI is higher and the error
under the same signal-to-noise ratio is lower compare
Fig 1 A SW image is developed from the combination of a magnitude image and a phase image
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with T2*-weighted imaging, often considered the gold
standard for the evaluation of brain iron content [34–38].
Thus, SWI is reliable for the clinical usage of evaluating
the iron content of deep brain nuclei. However, SWI
has drawbacks as well. The phase is not a local physical
property, because the phase of a certain region is affected
not only by the susceptibility of this region, but also by
that of the surrounding areas [23, 26, 39]. It means that
the phase image reflects comprehensive information about
susceptibility changes. Moreover, a process called convolu-
tion in the formation of phase image makes it very diffi-
cult to distinguish paramagnetic iron from diamagnetic
calcium [23]. Furthermore, the reproducibility is low,
because the phase can be affected by the orientation
of structures relative to the applied field [40].
To solve the problems of SWI, quantitative susceptibi-
lity mapping (QSM) is designed to quantify the iron
content through measuring the susceptibility of certain
areas directly [23, 39–43]. QSM is developed from SWI
by solving the ill-posed inverse effect-to-source problem.
Because the susceptibility is an intrinsic property of
tissue, QSM can produce more precise image avoiding
the non-locality of phase, and can differentiate iron from
calcium [23]. Moreover, QSM can avoid the effect of the
orientation relative to the applied field, due to the suscep-
tibility value in QSM is isotropic [26]. What’s more,
QSM shows a higher reproducibility compared with R2*
mapping to measure iron content [40]. Although this
technique may be useful for assessing iron in deep struc-
ture with high iron content, the diamagnetic myelin level
in white matter may impact the measurement. Little
research has been conducted about the application of
QSM for the diagnosis and differentiation of parkinsonism
[42–44]. Therefore, QSM has a very promising future to
study the parkinsonism-related iron deposition [36].
Brain iron deposition
Brain iron accumulation in the physiologic state
The brain iron distribution is uneven
The iron levels of basal ganglia are high [34, 45, 46].
Histological studies have shown that normally the caud-
ate nucleus (CN), the putamen (PUT), the globus pali-
dus (GP), the red nucleus (RN), and the substantia nigra
(SN) are rich in iron, while the iron content of cortex is
relatively low [45, 46]. In the cortex, the motor cortex
(MC) is richest in iron, while the prefrontal and tem-
poral cortices are the poorest [45]. Although the exact
order of the iron level of deep nuclei does not reach a
consensus between postmortem studies, those studies
imply the heterogeneous distribution of brain iron in
normal aging [45, 46].
Even within the same deep brain nuclei, the iron
distribution is uneven. Histological studies reveal that
the SN pars reticulata (SNr) in the ventral SN is rich
in iron, while the SNc in the dorsol SN is poor [47, 48].
Zecca et al. reported that the neuromelanin is the major
iron-stored place in the SN neurons [49]. According to
these facts, it is concluded that physiologically, iron depo-
sition is heterogeneous, even in the same deep brain
nuclei like SN.
The speed of brain iron deposition is uneven
A bunch of studies have approved that the speed of iron
deposition across the brain is not even. In SN and GP,
the iron concentration grows quickly in the early 20
years of life, then more gradually, and stops after 30
years of age [45, 49]. For CN and PUT, the maximal
speed of iron accumulation was during the first 50 to 60
years old of life [45]. In some areas of the brain, iron
deposition occurs through the whole life span. Interest-
ingly, the iron content of the medulla oblongata is low
and does not increase with advancing of age [45, 46].
The function of the brain iron
Iron functioning in the brain mainly exists in the forms
of hemoglobin, iron-containing enzyme and non-haemin
iron [13, 28, 45]. The iron involved in normal aging
and neurodegenerative parkinsonism belongs to the non-
haemin which is a cofactor of several enzymes that are
associated with myelin formation and neurotransmitter
production [13, 27–29, 45, 50, 51]. The period of the
fastest iron deposition coincides with when the myelin
of the brain forms the fastest in the early stage of life
[12, 29, 45]. There is other evidence that iron deficiency
can impair neural development, behavioral and cognitive
function probably via damage to the myelin formation
and neurotransmitter production [28].
Brain iron deposition in neurodegenerative parkinsonism
Brain iron accumulation in PD
Pathological and MRI studies indicate that the SN is the
most relevant area of the brain in PD [17, 49, 52–55].
The iron concentration of the SN on the affected side
of PD is approximately 80% more than that in healthy
controls (HC), while overall iron contents in the brain
between PD and HC are close [2, 31]. The reason for this
phenomenon is unclear, but the elevated iron level of
SN may relate to the localized pathogenesis such as
permeability changes of the blood brain barrier (BBB),
inflammation state, gene mutation-induced abnormal pro-
tein function in iron storage and transport, etc. [56–58]
Furthermore, excess iron can cause cell death through
reactive oxygen species derived from Fenton’s reaction
by which iron catalyzes hydrogen peroxide [11–13, 27, 29].
Notably, an insight into the relationship between the
ferric (III) or ferrous (II) state of iron and alpha-synuclein
enables a better understanding of the pathogenesis of
PD. Fe (II) takes part in the Fenton reaction producing
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hydrogen peroxide, and then Fe (II) is oxidized to Fe (III).
Levin et al. reported that alpha-synuclein aggregation is
independent of oxidizing agents, while is highly correlated
with the amount of Fe (III) [59]. This is in line with
the fact that the Fe2+/Fe3+ ratio shift to the Fe3+ in PD
[59, 60]. Iron chelators can protect neurons from death in
vitro, and PD patients may benefit from the decrease in
iron level [12, 61, 62]. Some researchers believe that
a localized, elevated iron level is caused by the iron-
chelated neuromelanin that is released from dead
neurones injured by aggregation of alpha-synuclein [54].
In this case, the increased extracellular neuromelanin is
the cause of elevated iron level. In contrary, others
suggested that the iron level increased primarily, and then
neuromelanin increased as a compensatory factor to
chelate redundant iron [11]. It is still debatable whether
abnormal iron deposition is the primary cause of neuro-
pathology or just an epiphenomenon [12, 13].
Brain iron accumulation in APD
MSA and PSP are the most common APD and clinically
the most important differential diagnosis for PD [48].
Autopsy research suggested that brownish discoloration
of deep brain nuclei relates to iron deposition [48, 63].
In MSA, discoloration and atrophy of posteriolateral
PUT was remarkable compared with PD and PSP in
autopsy [48, 63, 64]. However, neither discoloration nor
atrophy of RN, dendate nucleus (DN) and subthalamic
nucleus (STN) were found in MSA [48, 63, 64]. In PSP,
remarkable atrophy and discoloration were revealed in
cerebellar WM and STN [65–68]. Both MSA and PSP
showed various degrees of the atrophy of SN, GP, TH and
CN [48, 63–66, 68]. More researches are needed to further
specify the spatial distribution of iron deposition in APD.
SWI in Parkinson’s disease and atypical
parkinsonian disorders
SWI in the diagnosis of Parkinson’s disease
The majority of research approved that SWI was feasible
to indirectly quantify the iron content of different regions
of brain through comparing the phase values in SWI
which was highly correlated with the iron content [17, 19,
22, 24]. Thus, the comparison of iron content in SWI
is conducted by comparing the phase value indirectly
rather than by comparing the iron content directly like
QSM. There are various forms of iron deposition patterns
of PD imaged by SWI among the researches. Some
researches supported that iron deposition patterns in
SWI can distinguish PD from HC. Jiuquan Zhang et al.
reported that the iron concentration was elevated signifi-
cantly only in the SN of PD compared with HC in
SWI [17]. The iron contents of the SNc, CN and RN in
PD were significantly higher than those in HC in a SWI
study by Wei Zhang et al. [33]. Also, Wu et al.
demonstrated the iron accumulation in the SN, RN, CN,
PUT, and GP of PD was more remarkable than that of HC
[69]. An elevated iron level of the SN was common in PD
among SWI research, because the SN is the most patho-
logically relevant site of PD and become atrophy and
brownish discoloration in autopsy [48, 67, 70]. Notably,
Dashtipour et al. did not find remarkably increased iron
content of SN in PD, and it may be explained by the small
sample size [31]. However, the discrepancy of iron accu-
mulation in other nuclei, such as RN, CN, PUT, and GP,
in SWI is unclear. One possible reason is that deep brain
nuclei are pathologically involved simultaneously with
different degrees of iron accumulation [70]. In addition,
different iron deposition patterns may relate to disease
progression [31]. Furthermore, research has demonstrated
that the iron content of the SN is inversely correlated with
the severity of PD as measured by UPDRS-motor score
and H-Y stage [17, 30, 48], while no correlations were
found between the iron content of the SN and the
duration, progression, prognosis and levodopa response of
PD [17, 31, 33, 69, 71, 72]. Even though with the hetero-
geneity of iron deposition speed and distribution in the
whole disease process, SWI still fails to characterize
specific clinical features of PD. For instance, SWI
cannot detect the difference between earlier-onset and
later-onset PD patients [17]. Neither could SWI show
difference between the early and intermediate/advanced
stages of PD [69]. Mechanisms, such as gene mutation,
alteration of the BBB, and inflammation, may underlie
the speed, onset and spatial distribution of iron deposition
[12, 29, 50]. Further studies are needed to figure out
whether there are correlations between iron content of
SN and specific clinical features.
In recent years, a novel imaging biomarker called
nigrosome 1, which is the sub-region of the SN, has been
extensively studied by researchers. According to the
immuno-staining of calbindin that can bind to calcium,
the SNc is subdivided into nigrosome (caldbindin-poor)
and nigral matrix (caldbindin-rich). Nigrosome 1 is the
largest nigrosome containing the biggest group of dopa-
minergic cells and is affected in almost every PD patient
[73]. It was reported that 7T MRI could visualize the
three-layered structure of SN and could distinguish
patients with PD from HC with both high sensitivity
and specificity [14, 74, 75]. In 3T SWI, nigrosome 1
also shows dorsolateral hyperintensity of SN in HC, and
disappears in PD with 100% sensitivity and high specificity
(shown in Fig. 2) [47, 73]. These evidences suggested that
3T SWI is a reliable tool for the visualization of nigrosome
1 and the diagnosis of PD. However, in some studies
nigrosome 1 hyperintensity also disappears in MSA-P
and PSP in SWI [14, 53]. Therefore, nigrosome 1 is a safe
biomarker for neurodegenerative parkinsonism rather
than PD.
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SWI in the differentiation of PD from APD
The iron deposition patterns of MSA-P imaged by SWI
At present, the most promising signs in SWI that
characterize MSA-P focus on signal changes in PUT due
to its remarkably high iron level demonstrated by autopsy
[32, 48, 63, 76]. As the mechanism of SWI, the signal
intensity of certain region is decreased when paramagnetic
iron accumulates. Researchers designed a visual scale
of the PUT hypointensity for visual differentiation
[71, 76, 77]. The visual scales contain a set of standard
images of putaminal hypointensity graded from 0 to 3.
The higher the grade reaches, the lower the signal inten-
sity is [71, 76, 77]. Grade 3 hypointensity of the posterior
PUT was reported to discriminate MSA-P from PD [77].
This finding was consistent with the iron deposition
pattern of MSA-P in autopsy that the iron content of
posterior PUT in MSA-P was remarkably higher than
that in PD [48, 63, 64]. Some researchers even suggested
more detailed criteria for differentiation. For example,
Wang et al. reported that when the PUT was sub-divided
into 4 regions (lower inner, lower outer, upper inner and
upper outer), the lower inner part of the PUT performed
the best on receiver operating characteristic curve to
distinguish MSA-P from PD [72]. Except for the studies
about the iron levels in the local areas of PUT, Han et al.
found that the topography of iron deposition of the PUT
showing posteriolateral-to-anteriomedial ascending signal
intensity, was highly specific for MSA-P patients, even in
the early stage without obvious clinical symptoms [32].
Although the aforementioned biomarkers are still contro-
versial and need further validation, they are still by far the
most promising biomarkers and are clinically available.
It was even suggested by Yoon et al. that SWI was
potentially able to replace PET in the diagnosis of MSA-P
because in PUT there was positive correlation between a
low metabolism rate in PET and the low signal intensity
in SWI [16]. However, Kwon et al. found no correlation
between the metabolism rate in PET and the signal inten-
sity in SWI [78]. The potential that SWI indicates the
dysfunction of dopaminergic neurons imaged by PET
needs further studies.
Other deep nuclei, such as the CN and pulvinar TH
(PT), were also studied. Meijer et al. reported that the
iron content of the CN on the affected side of MSA-P
was remarkably higher than that of PD in SWI [77]. By
contrast, Wang et al. demonstrated that the iron content
of the CN cannot distinguish MSA-P from PD in SWI
[72]. On autopsy, neuronal loss of the CN correlated
with iron deposition is common and severe in MSA-P
but unusual and mild in PD [12, 48]. The discrepancies
between different studies may come from the variety
of inclusion criteria, with patients at different MSA-P
stages. Only a few study investigated about PT. Wang
et al. found that the higher iron content of the PT in
MSA-P, but failed to show statistical significance between
groups [72]. For CN and PT, more researches are war-
ranted to validate their potentials as biomarkers.
The iron deposition patterns of PSP imaged by SWI
There are different iron deposition patterns of PSP in
SWI because of various forms of neuropathological
processes [65]. Meijer et al. reported that elevated iron
levels of the RN and dentate nucleus (DN) on the affected
side could distinguish PSP from PD [77]. These findings
are consistent with the pathological results of Dickson
that only the RN and DN were damaged consistently and
severely in PSP, but were spared in PD and MSA [48].
Gupta et al. found that increased iron content of the RN
and the PUT was able to differentiate PSP from MSA-P
and PD [71]. Notably, the iron level of the PUT is
suggested to be the biomarker for the diagnosis of
MSA-P in many studies [32, 48, 63, 76]. One possible
speculation for this controversy is that local iron content
and specific deposition patterns such as dense iron depo-
sition in lower outer part of PUT, are more specific than
overall content in MSA-P, while the overall iron content
of PUT is a characteristic feature for PSP [71, 76, 77].
In addition, Han et al. demonstrated that elevated iron
contents of GP and TH were the most valuable bio-
markers in SWI to differentiate PSP from MSA-P and
PD [32]. From neuropathological studies, neuronal loss of
GP and TH is more severe in PSP than in MSA, but
spared in PD [48, 63, 66]. However, due to the diverse
results, consensus regarding the features of SWI imaging
for PSP is hard to reach and further studies aiming at
finding SWI biomarkers should consider the disease
stage and combine the SWI results with iron-related
neuropathology.
The drawbacks among SWI research
SWI is a promising biomarker that provides more infor-
mation for early and differential diagnosis of parkinso-
nism, however present studies have several drawbacks
Fig 2 Nigrosome 1 of three-layered structure disappears in PD
patients, while it exists in health controls (which are pointed out by
black arrows)
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that need to be addressed in the future. (1) Few research
combined the SWI results of parkinsonism with patho-
logical investigations [32, 71]. (2) Most of patients in-
volved in studies have received levodopa replacement
therapy, which may change the iron deposition pattern
in SWI [17]. (3) Most of the studies are retrospective
[72], and the follow-up of a few prospective studies are
relatively short [8]. (4) The difference in scan parameters
of SWI such as slice thickness, matrix size, etc., should
be considered to interpret the discrepancy of results
[17, 69]. Also, standardization for regions of interest
drawn by hand and uniformed image analysis should
be applied [33].
Conclusion
SWI characterizes brain iron deposition patterns of
PD to illustrate the iron-related pathologic alterations
in vivo and compensates for some drawbacks of routine
MRI. Many researches have confirmed that SWI is a
promising tool for the diagnosis and differential diagnosis
of PD through discovering iron-related biomarkers, and
more accessible in the clinic. Further studies should
take the stages of neurodegenerative parkinsonism into
consideration to acquire better correlations between SWI
findings and neuropathologic results. With the underling
pathological procedures illustrated by SWI, it will be
possible to diagnose PD in the early stage and differentiate
PD from APD.
Abbreviations
APD: Atypical parkinsonian disorders; BBB: Blood brain barrier; CN: Caudate
nucleus; DN: Dentate nucleus; GM: Grey matter; GP: Globus pallidus;
HC: Healthy controls; LC: Locus coeruleus; MC: Motor cortex; MSA-P: Multiple
system atrophy parkinsonian predominant type; PD: Parkinson's disease;
PSP: Progressive supranuclear palsy; PT: Pulvinar thalamus; PUT: Putamen;
RN: Red nucleus; SN: Substantia nigra; SNc: SN pars compacta; SNr: SN pars
reticulate; STN: Subthalamic nucleus; SWI: Susceptibility-weighted imaging;




This work was funded by China National Nature Science Fund
(No. 81371421). The role of this funding body was in writing
the manuscript.
Availability of data and material
Data sharing not applicable to this article as no datasets were generated or
analyzed during the current study.
Authors’ contributions
ZBW: draft the manuscript. XGL: raised the idea of this review and revised
the manuscript. CG: revised the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Neurology Department, The First Affiliated Hospital of China Medical
University, 155# Nanjing Bei Street Heping District, Shenyang 110001,
People’s Republic of China. 2Neurology Department, Ruijin Hospital, Shanghai
Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai
200025, People’s Republic of China.
Received: 28 June 2016 Accepted: 29 September 2016
References
1. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease.
Neurodegener Dis. 2010;7:284–90.
2. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s disease.
Biochim Biophys Acta. 2009;1792:722–9.
3. Salat D, Noyce AJ, Schrag A, Tolosa E. Challenges of modifying disease
progression in prediagnostic Parkinson's disease. Lancet Neurol.
2016;15:637–48.
4. David R, Williams M, Litvan I. Parkinsonian Syndromes. Continuum.
2013;19:1189–212.
5. S. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to
the understanding of the pathophysiology of Parkinson’s disease.
Neurophysiol Clin. 2001;31:321–40.
6. Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes
Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane
on diagnosis and management of patients with clinically uncertain
Parkinsonian syndromes. Mov Disord. 2004;19:1175–82.
7. Morelli M, Arabia G, Salsone M, Novellino F, Giofre L, Paletta R, et al.
Accuracy of magnetic resonance parkinsonism index for differentiation of
progressive supranuclear palsy from probable or possible Parkinson disease.
Mov Disord. 2011;26:527–33.
8. Meijer FJ, Aerts MB, Abdo WF, Prokop M, Borm GF, Esselink RA, et al.
Contribution of routine brain MRI to the differential diagnosis of parkinsonism:
a 3-year prospective follow-up study. J Neurol. 2012;259:929–35.
9. Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, Daniel SE, Quinn NP.
Clinical usefulness of magnetic resonance imaging in multiple system
atrophy. J Neurol Neurosurg Psychiatry. 1998;65:65–71.
10. Lhermitte J, Kraus WM, McAlpine D. On the occurrence of abnormal
deposits of iron in the brain in parkinsonism with special referene to its
localisation. J Neurol Psychopathol. 1924;5:195–208.
11. Zucca FA, Segura-Aguilar J, Ferrari E, Munoz P, Paris I, Sulzer D, et al.
Interactions of iron, dopamine and neuromelanin pathways in brain
aging and Parkinson's disease. Prog Neurobiol. 2015. doi:10.1016/j.
pneurobio.2015.09.012.
12. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain
ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045–60.
13. Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural
Transm. 2016;123:389–99.
14. Kim JM, Jeong HJ, Bae YJ, Park SY, Kim E, Kang SY, et al. Loss of substantia
nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system
atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord.
2016;26:47–54.
15. Boelmans K, Holst B, Hackius M, Finsterbusch J, Gerloff C, Fiehler J, et al.
Brain iron deposition fingerprints in Parkinson's disease and progressive
supranuclear palsy. Mov Disord. 2012;27:421–7.
16. Yoon RG, Kim SJ, Kim HS, Choi CG, Kim JS, Oh J, et al. The utility of
susceptibility-weighted imaging for differentiating Parkinsonism-
predominant multiple system atrophy from Parkinson's disease: correlation
with 18F-flurodeoxyglucose positron-emission tomography. Neurosci Lett.
2015;584:296–301.
17. Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, et al. Characterizing iron
deposition in Parkinson's disease using susceptibility-weighted imaging:
an in vivo MR study. Brain Res. 2010;1330:124–30.
18. Haacke EM, Xu Y, Cheng Y-CN, Reichenbach Jr R. Susceptibility weighted
imaging (SWI). Magn Reson Med. 2004;52:612–8.
19. Tuite PJ, Mangia S, Michaeli S. Magnetic Resonance Imaging (MRI) in
Parkinson’s Disease. J Alzheimer’s Dis Parkinsonism. 2013;Suppl 1:001.
Wang et al. Translational Neurodegeneration  (2016) 5:17 Page 6 of 8
20. Vertinsky AT, Coenen VA, Lang DJ, Kolind S, Honey CR, Li D, et al.
Localization of the subthalamic nucleus: optimization with susceptibility-
weighted phase MR imaging. AJNR Am J Neuroradiol. 2009;30:1717–24.
21. Cosottini M, Frosini D, Pesaresi I, Donatelli G, Cecchi P, Costagli M, et al.
Comparison of 3T and 7T susceptibility-weighted angiography of the
substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol.
2015;36:461–6.
22. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YCN. Susceptibility-weighted
imaging: technical aspects and clinical applications, part 1. AJNR Am J
Neuroradiol. 2008;30:19–30.
23. Liu C, Li W, Tong KA, Yeom KW, Kuzminski S. Susceptibility-weighted
imaging and quantitative susceptibility mapping in the brain. J Magn
Reson Imaging. 2015;42:23–41.
24. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging:
technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol.
2009;30:232–52.
25. Shmueli K, de Zwart JA, van Gelderen P, Li TQ, Dodd SJ, Duyn JH. Magnetic
susceptibility mapping of brain tissue in vivo using MRI phase data.
Magn Reson Med. 2009;62:1510–22.
26. Schweser F, Deistung A, Lehr BW, Reichenbach JR. Quantitative imaging of
intrinsic magnetic tissue properties using MRI signal phase: an approach to
in vivo brain iron metabolism? Neuroimage. 2011;54:2789–807.
27. Dusek P, Roos PM, Litwin T, Schneider SA, Flaten TP, Aaseth J. The
neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s
diseases. J Trace Elem Med Biol. 2015;31:193–203.
28. Hagemeier J, Geurts JJ, Zivadinov R. Brain iron accumulation in aging and
neurodegenerative disorders. Expert Rev Neurother. 2012;12:1467–80.
29. Kruer MC. The neuropathology of neurodegeneration with brain iron
accumulation. Int Rev Neurobiol. 2013;110:165–94.
30. Dabrowska M, Schinwelski M, Sitek EJ, Muraszko-Klaudel A, Brockhuis B, Jamrozik
Z, et al. The role of neuroimaging in the diagnosis of the atypical parkinsonian
syndromes in clinical practice. Neurol Neurochir Pol. 2015;49:421–31.
31. Dashtipour K, Liu M, Kani C, Dalaie P, Obenaus A, Simmons D, et al. Iron
accumulation is not homogenous among patients with Parkinson’s disease.
Parkinson’s Dis. 2015;2015:324843.
32. Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, et al. Topographical
differences of brain iron deposition between progressive supranuclear palsy
and parkinsonian variant multiple system atrophy. J Neurol Sci. 2013;325:29–35.
33. Zhang W, Sun SG, Jiang YH, Qiao X, Sun X, Wu Y. Determination of brain
iron content in patients with Parkinson's disease using magnetic
susceptibility imaging. Neurosci Bull. 2009;25:353–60.
34. Haacke EM, Ayaz M, Khan A, Manova ES, Krishnamurthy B, Gollapalli L,
Ciulla C, Kim I, Petersen F, Kirsch W. Establishing a baseline phase behavior
in magnetic resonance imaging to determine normal vs. abnormal iron
content in the brain. J Magn Reson Imaging. 2007;26:256–64.
35. Pirpamer L, Hofer E, Gesierich B, De Guio F, Freudenberger P, Seiler S, et al.
Determinants of iron accumulation in the normal aging brain. Neurobiol
Aging. 2016;43:149–55.
36. Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, et al.
Quantifying brain iron deposition in patients with Parkinson's disease
using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging.
2015;33:559–65.
37. Ning N, Zhang L, Gao J, Zhang Y, Ren Z, Niu G, et al. Assessment of iron
deposition and white matter maturation in infant brains by using
enhanced T2 star weighted angiography (ESWAN): R2* versus phase values.
PLoS One. 2014;9:e89888.
38. Wang C, Fan G, Xu K, Wang S. Quantitative assessment of iron deposition in
the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN):
a preliminary cross-sectional study of 20 Parkinson's disease patients.
Magn Reson Imaging. 2013;31:1068–73.
39. Reichenbach JR, Schweser F, Serres B, Deistung A. Quantitative susceptibility
mapping: concepts and applications. Clin Neuroradiol. 2015;25 Suppl 2:225–30.
40. Santin MD, Didier M, Valabregue R, Yahia Cherif L, Garcia-Lorenzo D,
Loureiro de Sousa P, et al. Reproducibility of R2 * and quantitative
susceptibility mapping (QSM) reconstruction methods in the basal ganglia
of healthy subjects. NMR Biomed. 2016. doi:10.1002/nbm.3491.
41. Deistung A, Schweser F, Reichenbach JR. Overview of quantitative
susceptibility mapping. NMR Biomed. 2016. doi:10.1002/nbm.3569.
42. Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, et al. Quantitative
susceptibility mapping of the midbrain in Parkinson’s disease.
Mov Disord. 2016;31:317–24.
43. Guan X, Xuan M, Gu Q, Huang P, Liu C, Wang N, et al. Regionally
progressive accumulation of iron in Parkinson's disease as measured by
quantitative susceptibility mapping. NMR Biomed. 2016. doi:10.1002/nbm.3489.
44. Azuma M, Hirai T, Yamada K, Yamashita S, Ando Y, Tateishi M, et al. Lateral
asymmetry and spatial difference of iron deposition in the substantia nigra
of patients with Parkinson disease measured with quantitative susceptibility
mapping. AJNR Am J Neuroradiol. 2016;37:782–8.
45. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the
human brain. J Neurochem. 1958;3:41–51.
46. Ramos P, Santos A, Pinto NR, Mendes R, Magalhães T, Almeida A. Iron levels
in the human brain: A post-mortem study of anatomical region differences
and age-related changes. J Trace Elem Med Biol. 2014;28:13–7.
47. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, et al.
Visualization of nigrosome 1 and its loss in PD. Neurology. 2013;81:534–40.
48. Dickson DW. Parkinson’s disease and Parkinsonism: Neuropathology. Cold
Spring Harb Perspect Med. 2012. doi:10.1101/cshperspect.a009258.
49. Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P,
Vezzoni P, Tampellini D. Iron, neuromelanin and ferritin content in the
substantia nigra of normal subjects at different ages: consequences for iron
storage and neurodegenerative processes. J Neurochem. 2001;76:1766–73.
50. Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the
brain. Curr Opin Neurol. 2004;17:437–42.
51. Heidari M, Gerami SH, Bassett B, Graham RM, Chua AC, Aryal R, et al.
Pathological relationships involving iron and myelin may constitute a
shared mechanism linking various rare and common brain diseases.
Rare Dis. 2016;4:e1198458.
52. Jin L, Wang J, Jin H, Fei G, Zhang Y, Chen W, et al. Nigral iron deposition occurs
across motor phenotypes of Parkinson's disease. Eur J Neurol. 2012;19:969–76.
53. Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, et al.
Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in
neurodegenerative Parkinsonism. Mov Disord. 2015;30:1068–76.
54. Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, et al. Correlation
between pathology and neuromelanin MR imaging in Parkinson's disease
and dementia with Lewy bodies. Neuroradiology. 2013;55:947–53.
55. Zeccaa L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute
concentration of nigral neuromelanin, assayed by a new sensitive method,
increases throughout the life and is dramatically decreased in Parkinson's
disease. FEBS Lett. 2002;510:216–20.
56. Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP.
Genetics and Pathophysiology of Neurodegeneration with Brain Iron
Accumulation (NBIA). Curr Neuropharmacol. 2013;11:59–79.
57. Duck KA, Connor JR. Iron uptake and transport across physiological barriers.
Biometals. 2016;29:573–91.
58. Hu Y, Yu SY, Zuo LJ, Piao YS, Cao CJ, Wang F, et al. Investigation on
abnormal iron metabolism and related inflammation in Parkinson disease
patients with probable RBD. PLoS One. 2015;10:e0138997.
59. Levin J, Hogen T, Hillmer AS, Bader B, Schmidt F, Kamp F, et al. Generation
of ferric iron links oxidative stress to alpha-synuclein oligomer formation.
J Parkinson’s Dis. 2011;1:205–16.
60. Peng Y, Wang C, Xu HH, Liu YN, Zhou F. Binding of alpha-synuclein with
Fe(III) and with Fe(II) and biological implications of the resultant complexes.
J Inorg Biochem. 2010;104:365–70.
61. Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of
neurodegenerative diseases. J Trace Elem Med Biol. 2016. doi:10.1016/j.
jtemb.2016.03.010.
62. Aguirre P, Mena NP, Carrasco CM, Munoz Y, Perez-Henriquez P, Morales RA,
et al. Iron Chelators and Antioxidants Regenerate Neuritic Tree and
Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons.
PLoS One. 2015;10:e0144848.
63. Jellinger KA. Neuropathology of multiple system atrophy: new thoughts
about pathogenesis. Mov Disord. 2014;29:1720–41.
64. Benarroch EE. New findings on the neuropathology of multiple system
atrophy. Auton Neurosci. 2002;96:59–62.
65. Wakabayashi K, Takahashi H. Pathological heterogeneity in progressive
supranuclear palsy and corticobasal degeneration. Neuropathology.
2004;24:79–86.
66. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy:
pathology and genetics. Brain Pathol. 2007;17:74–82.
67. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of
sporadic Parkinson disease before the appearance of parkinsonism:
preclinical Parkinson disease. J Neural Transm. 2011;118:821–39.
Wang et al. Translational Neurodegeneration  (2016) 5:17 Page 7 of 8
68. Collins SJ, Ahlsog JE, Parisi JE, Maraganore DM. Progressive supranuclear
palsy: neuropathologically based diagnostic clinical criteria. J Neurol
Neurosurg Psychiatry. 1995;58:167–73.
69. Wu SF, Zhu ZF, Kong Y, Zhang HP, Zhou GQ, Jiang QT, Meng XP. Assessment
of cerebral iron content in patients with Parkinson’s disease by the
susceptibility-weighted MRI. Eur Rev Med Pharmacol Sci. 2014;18:2605–8.
70. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E.
Staging of brain pathology related to sporadic Parkinson’s disease.
Neurobiol Aging. 2003;24:197–211.
71. Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of
susceptibility-weighted MRI in differentiating Parkinson's disease
and atypical parkinsonism. Neuroradiology. 2010;52:1087–94.
72. Wang Y, Butros SR, Shuai X, Dai Y, Chen C, Liu M, et al. Different
iron-deposition patterns of multiple system atrophy with predominant
parkinsonism and idiopathetic Parkinson diseases demonstrated by
phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol.
2012;33:266–73.
73. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The
‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test
of Parkinson’s Disease: A Case-control and Retrospective Cross-Sectional MRI
Study at 3T. PLoS One. 2014;9:e93814.
74. Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 Tesla magnetic
resonance imaging: a closer look at substantia nigra anatomy in Parkinson's
disease. Mov Disord. 2014;29:1574–81.
75. Mirco Cosottini M, Daniela Frosini M, Ilaria Pesaresi M, Mauro Costagli P,
Laura Biagi P, Roberto Ceravolo M, et al. MR Imaging of the Substantia
Nigra at 7 T Enables Diagnosis of Parkinson Disease. Radiology.
2014;271:831–8.
76. Leea J-H, Baikb S-K. Putaminal Hypointensity in the Parkinsonian Variant
of Multiple System Atrophy: Simple Visual Assessment Using
Susceptibility-Weighted Imaging. J Mov Disord. 2011;4:60–3.
77. Meijer FJ, van Rumund A, Fasen BA, Titulaer I, Aerts M, Esselink R, et al.
Susceptibility-weighted imaging improves the diagnostic accuracy of 3T
brain MRI in the work-up of parkinsonism. AJNR Am J Neuroradiol.
2015;36:454–60.
78. Kwon GH, Jang J, Choi HS, Hwang EJ, Jung SL, Ahn KJ, Kim BS, Yoo IR,
Kim SH, Haacke EM. The phase value of putamen measured by susceptibility
weighted images in Parkinson’s disease and in other forms of Parkinsonism:
a correlation study with F18 FP-CIT PET. Acta Radiol. 2015.
doi:10.1177/0284185115604515.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Translational Neurodegeneration  (2016) 5:17 Page 8 of 8
